Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Will a TIGIT refocus see the stars finally align for the partners?
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?